July 02, 2026 — RNews

#neuroendocrine — Thursday, July 02, 2026 (1 items)

hot top new

← prev day next day →

0

[(177)Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. (linkinghub.elsevier.com)

Walter T … Capdevila J The Lancet 2026-07-02

#clinical trial #neuroendocrine #radionuclide #cancer #targeted therapy